Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Antitumor efficacy of ABX-EGF in metastatic renal cancer

Sep. 1, 2004

Aphton seeks Canadian registration of Insegia in pancreatic cancer

Aug. 30, 2004

SGN-40 receives orphan drug designation for multiple myeloma

Aug. 26, 2004

Medarex reaches SPA agreement for phase III trial of MDX-010

Aug. 26, 2004

Orphan drug status for HuMax-CD4

Aug. 24, 2004

Viragen updates Multiferon progress

Aug. 24, 2004

Bispecific antibody targets EGFR-positive bile duct carcinoma

Aug. 19, 2004

New phase II study for HuMax-CD4 in non-cutaneous T-cell lymphoma

Aug. 18, 2004

Baxter signs as contract manufacturer for Morphotek's MORAb-003

Aug. 16, 2004

European approval for MabThera for first-line treatment of indolent NHL

Aug. 12, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...